Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.54 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | CDC25B | P30305 | 3/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139702 | 0.90 | SLC5A2 (0.53) | SLC5A2SLC5A1TACR2 | |
| SCHEMBL20139415 | 0.88 | SLC5A2 (0.42) | SLC5A2SLC5A1PTPN1CDC25BPTPN2 | |
| SCHEMBL20140082 | 0.88 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL20139478 | 0.88 | SLC5A2 (0.41) | SLC5A2SLC5A1TACR2PTPN1CDC25B | |
| SCHEMBL20139482 | 0.87 | SLC5A2 (0.54) | SLC5A2SLC5A1PTPN1CDC25BPTPN2 | |
| SCHEMBL20140099 | 0.87 | SLC5A2 (0.40) | SLC5A2SLC5A1PTPN1CDC25BPTPN2 | |
| SCHEMBL20139981 | 0.86 | HTR1A (0.40) | SLC5A2SLC5A1TACR2PTPN1CDC25B | |
| SCHEMBL20139493 | 0.85 | SLC5A1 (0.44) | SLC5A2SLC5A1TACR2PTPN1CDC25B | |
| SCHEMBL20141043 | 0.85 | SLC5A2 (0.41) | SLC5A2SLC5A1PTPN1CDC25BPTPN2 | |
| SCHEMBL15610107 | 0.85 | SLC5A2 (0.54) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885TACR2 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.